As COVID-1 9 examples in the US continue to spike and doctors and researchers try to marshal any and all technological resources to help patients, understand the disease, and fight off the spread of the epidemic, one startup that monitors and assess medical invention technology is offering its services for free so physicians can understand the tools at their dumping.
San Francisco-based Elektra Labs was co-founded by a onetime official at the Food and Drug Administration and a Harvard-trained physician working at Massachusetts General Hospital, to provide clear and accurate assessments of the security, cogency, and viability of brand-new biosensors coming to market.
The company said that it will now make its assessments of medical inventions that are pitching evidence monitoring engineerings for COVID-1 9 available for free to clinicians and researchers.
As the number of infected beings in the US contacts 2.5 million and the ordeal situation that health professionals warned about become reality with capability in hospitals overtaken by sick cases, the healthcare industry is turning to digital works like telemedicine not because they want to, but because they must.
“The ability to reliably assesses patients’ vital signs remotely is a potent highway to improve the utility of telemedicine, ” said Elektra Labs co-founder Dr. Sofia Warner, who has been treating COVID-1 9 patients on the front line at Massachusetts General Hospital, in a statement. “Having a sense of what connected sensors are authenticated for which amounts is important for providers to know.”
Digital monitoring and technology implements aren’t just for treating cases. The pharmaceutical industry is using the same tech to help with clinical contests to experiment new pharmaceuticals and medications since in-person trials have ground to a halt.
“Many pharmaceutical companies operating large-scale, critical, and expensive clinical tests are quickly working to adapt their studies to maintain progress and maintain patients safe amid the pandemic, ” said Ariel Stern, PhD, module at the Harvard-MIT Center for Regulatory Sciences, in a statement posted. “These firms are hastening to determine which produces are not only safe and effective, but also easy for study participants to deploy at home.”
Elektra Labs has developed what amounts to a nutrition label for objective measures around the validation, usability, utility, security and data governance components of connected sensor and it actually wrote the methods used behind its scoring framework in Nature Digital Medicine earlier this year.
Backed by risk capital conglomerates including Founder Collective, Boost VC, Lux Capital, Maverick Ventures, Village Global and Arkitekt Ventures, the early stage startup has already encountered a welcome acknowledgment among pharmaceutical companies and researchers.
“Technology has moved faster than our ability to safeguard ourselves, ” said Elektra Labs CEO Andy Coravos. “I co-founded Elektra to make it easier and safer to care for people at home, and never has this been more important than during the COVID-1 9 crisis. I’m thrilled to donate use of the Atlas pulpit to those working to treat patients and innovate in healthcare throughout the pandemic.”
Unlike Apple’s initiative to label apps in the app collect based on the way they use and reuse personal data, Elektra Labs’ scoring and ranking information won’t be available to everyone.
Instead the data will be available only to clinicians moving to virtual care, researchers planning decentralized clinical ordeals and public health officials examining an instrument for population state monitoring.
The idea is to enable doctors and researchers to determine which biometric monitoring tools they might use to supplement video tours or trail patients in research studies actually are safe and effective for patients to use at home.